from the In Briefing link regarding today's ASH presentation:
Excellent hypomethylation was achieved with higher doses in the daily regimen up to the Biologically Effective Dose (:BED). BED was reached before the Maximum Tolerated Dose (MTD). Of the 17 heavily pretreated relapsed/refractory AML patients who were given therapeutic doses of SGI-110 and achieved adequate hypomethylation, 5 major responses were observed.
Impressive. Lower toxicity. Ability to reach BED before hitting MTD. 5/17 major responses.
"This is the only new hypomethylating agent now in advanced clinical development, and we are excited by the differentiated PK profile and the favorable safety profile so far in this study. We are looking forward to the results of the Phase 2 dose expansion part of the trial that is now ongoing," commented Dr. Hagop Kantarjian.
BTW, Dr. K is a very heavy hitter in AML/MDS.